Table 3.
Drug treatments used in the study groups
| DHF | SHF | Total | |
| Diuretics | 19/29 (66%) | 35/39 (90%) | 54/68 (79%) |
| β Blockers | 3/29 (10%) | 15/39 (38%) | 18/68 (26%) |
| Calcium channel antagonists | 4/29 (14%) | 6/39 (15%) | 10/68 (15%) |
| ACEI/AIIRA | 14/29 (48%) | 31/39 (79%) | 45/68 (66%) |
| Nitrates | 18/29 (62%) | 33/39 (85%) | 51/68 (75%) |
| Digoxin | 3/29 (10%) | 5/39 (13%) | 8/68 (12%) |
| Spironolactone | 6/29 (21%) | 6/39 (15%) | 12/68 (18%) |
| Amiodarone | 1/29 (3%) | 4/39 (10%) | 5/68 (7%) |
| Statins | 4/29 (14%) | 7/39 (18%) | 11/68 (16%) |
ACEI, angiotensin converting enzyme inhibitor; AIIRA, angiotensin II receptor antagonist; DHF, diastolic heart failure; SHF, systolic heart failure.